Milestone Pharmaceuticals Inc. (MIST): Price and Financial Metrics
GET POWR RATINGS... FREE!
MIST Stock Price Chart Interactive Chart >
MIST Price/Volume Stats
|Current price||$6.07||52-week high||$11.40|
|Prev. close||$6.11||52-week low||$3.18|
|Day high||$6.14||Avg. volume||87,906|
|50-day MA||$5.63||Dividend yield||N/A|
|200-day MA||$6.72||Market Cap||181.17M|
Milestone Pharmaceuticals Inc. (MIST) Company Bio
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.
MIST Latest News Stream
|Loading, please wait...|
MIST Latest Social Stream
View Full MIST Social Stream
Latest MIST News From Around the Web
Below are the latest news stories about Milestone Pharmaceuticals Inc that investors may wish to consider to help them evaluate MIST as an investment opportunity.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 4:00 PM ET. The conference will be held in a virtual meeting format.
Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 4:00 PM ET.
Milestone Pharmaceuticals Inc (NASDAQ: MIST) hit a major snag last March when its investigational etripamil nasal spray for episodes of rapid heart rate missed the primary endpoint. A year later, it’s touting new data on its secondary endpoints and a partnership with Ji Xing Pharmaceuticals to develop the candidate in China for paroxysmal supraventricular tachycardia (PSVT) and additional cardiovascular conditions. Ji Xing is paying $15 million upfront and making a $5 million equity investment for the rights to develop and commercialize etripamil, a fast-acting calcium channel blocker, in Greater China. The agreement involves milestone payments of up to $107.5 million. At ACC 2021, Milestone said etripamil had higher scores than placebo related to relief of specific symptoms associated ...
Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China
Milestone Pharmaceuticals Inc. announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals to develop and, if approved, commercialize the investigational drug etripamil in patients with paroxysmal supraventricular tachycardia and additional cardiovascular conditions in Greater China.
Statistically Significant Improvements in PSVT-Associated Symptoms and Less ER Visits Observed in Patients Treated with Etripamil Compared to Placebo in the NODE-301 Trial
MIST Price Returns